Schizophrenia does not adversely affect the treatment of women with breast cancer: A cohort study

Breast

Volumn 19, Issue 5, 2010, Pages 410-412

  Sharma, Anand ^a   Ngan, Sarah ^a   Nandoskar, Ashwini ^a   Lowdell, Charles ^a   Lewis, Jacqueline S ^a   Hogben, Katy ^a   Charles Coombes, R ^a   Stebbing, Justin ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Chemotherapy; Outcome; Prognosis; Schizophrenia; Treatment

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CLOZAPINE; DEXAMETHASONE; DOMPERIDONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE DERIVATIVE; OLANZAPINE; ONDANSETRON; PHENOTHIAZINE; PROGESTERONE RECEPTOR; QUETIAPINE; RISPERIDONE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; BREAST SURGERY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RESEARCH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COHORT ANALYSIS; DATA ANALYSIS; DEMOGRAPHY; FEMALE; HEALTH CARE DELIVERY; HISTOPATHOLOGY; HUMAN; INFORMED CONSENT; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MEDICAL RECORD REVIEW; PATIENT CARE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 77958536533     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.04.001     Document Type: Article

References (21)

1. Regier D.A., Narrow W.E., Rae D.S., Manderscheid R.W., Locke B.Z., Goodwin F.K. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993, 50:85-94.
2. Saha S., Chant D., Welham J., McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005, 2:e141.
3. McGrath J., Saha S., Welham J., El Saadi O., MacCauley C., Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004, 2:13.
4. Guest J.C., Cookson R.F. Cost of Schizophrenia to UK society: an incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 1995, 15:597.
5. Cancer statistics registrations: registrations of cancer diagnosed in 2006, England 2009, Series MB1, Office for National Statistics, London.
6. Meyer F., Brown J.B., Morrison A.S., MacMahon B. Endogenous sex hormones, prolactin, and breast cancer in premenopausal women. J Natl Cancer Inst 1986, 77:613-616.
7. Schyve P.M., Smithline F., Meltzer H.Y. Prolactin and breast cancer. Psychopharmacol Bull. 1978, 14:17-19.
8. Adams J.B. Human breast cancer: concerted role of diet, prolactin and adrenal C19-delta 5-steroids in tumorigenesis. Int J Cancer 1992, 50:854-858.
9. Group S.S.R. Smoking habits and plasma lipid peroxide and vitamin E levels in never-treated first-episode patients with schizophrenia. Scottish Schizophrenia Research Group. Br J Psychiatry 2000, 176:290-293.
10. Brown S., Birtwistle J., Roe L., Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999, 29:697-701.
11. Chochinov H.M., Martens J.P., Prior H.J., Fransoo R., Burland E. Does a diagnosis of schizophrenia reduce rates of mammography screening? a Manitoba population-based study. Schizophr Res 2009, 113:95-100.
12. Inagaki T., Yasukawa R., Okazaki S., Yasuda H., Kawamukai T., Utani E., et al. Factors disturbing treatment for cancer in patients with schizophrenia. Psychiatry Clin Neurosci 2006, 60:327-331.
13. Bushe C.J., Bradley A.J., Wildgust H.J., Hodgson R.E. Schizophrenia and breast cancer incidence: a systematic review of clinical studies. Schizophr Res 2009, 114:6.
14. American Psychiatric Association Diagnositic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington, DC, ed 4th, Text revision.
15. Lee B., Franklin I., Lewis J.S., Coombes R.C., Leonard R., Gishen P., et al. The efficacy of percutaneous vertebroplasty for vertebral metastases associated with solid malignancies. Eur J Cancer 2009, 45:1597-1602.
16. Lee B., Lim A., Lalvani A., Descamps M.J., Leonard R., Nallamala S., et al. The clinical significance of radiologically detected silent pulmonary nodules in early breast cancer. Ann Oncol 2008, 19:2001-2006.
17. Tuthill M., Pell R., Guiliani R., Lim A., Gudi M., Contractor K.B., et al. Peritoneal disease in breast cancer: a specific entity with an extremely poor prognosis. Eur J Cancer 2009.
18. Punglia R.S., Morrow M., Winer E.P., Harris J.R. Local therapy and survival in breast cancer. N Engl J Med 2007, 356:2399-2405.
19. Moini B., Levenson J.L. A forgotten diagnosis: simple schizophrenia in a patient with breast cancer. Psychosomatics 2009, 50:87-89.
20. Kunkel E.J., Woods C.M., Rodgers C., Myers R.E. Consultations for 'maladaptive denial of illness' in patients with cancer: psychiatric disorders that result in noncompliance. Psychooncology 1997, 6:139-149.
21. Wang P.S., Walker A.M., Ming T., Tsuang M.T., Orav E.J., Glynn R.J., et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002, 59:1147-1154.